Also, CB-103 was more effective than either DAPT or RIN1 in Jurkat and KOPT-K1, but not Rec1 lines, suggesting differential roles of the NOTCH pathway components across cancer lines with activating NOTCH mutations. The gene discussed is KRT1; the disease is cancer.